Antiproliferative and cytotoxic effects of resveratrol in mitochondria-mediated apoptosis in rat b103 neuroblastoma cells

Resveratrol, a natural compound, has been shown to possess anti-cancer, anti-aging, anti-inflammatory, anti-microbial, and neuroprotective activities. In this study, we examined the antiproliferative and cytotoxicity properties of resveratrol in Rat B103 neuroblastoma cells; although it's molec...

Full description

Saved in:
Bibliographic Details
Published inThe Korean journal of physiology & pharmacology Vol. 16; no. 5; pp. 321 - 326
Main Authors Rahman, Md Ataur, Kim, Nam-Ho, Kim, Seung-Hyuk, Oh, Sung-Min, Huh, Sung-Oh
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Physiological Society and The Korean Society of Pharmacology 01.10.2012
대한약리학회
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Resveratrol, a natural compound, has been shown to possess anti-cancer, anti-aging, anti-inflammatory, anti-microbial, and neuroprotective activities. In this study, we examined the antiproliferative and cytotoxicity properties of resveratrol in Rat B103 neuroblastoma cells; although it's molecular mechanisms for the biological effects are not fully defined. Here, we examined the cellular cytotoxicity of resveratrol by cell viability assay, antiproliferation by BrdU assay, DNA fragmentation by DNA ladder assay, activation of caspases and Bcl-2 family proteins were detected by western blot analyses. The results of our investigation suggest that resveratrol increased cellular cytotoxicity of Rat B103 neuroblastoma cells in a dose-and time-dependent manner with IC(50) of 17.86 µM at 48 h. On the other hand, incubation of neuroblastoma cells with resveratrol resulted in S-phase cell cycle arrests which dose-dependently and significantly reduced BrdU positive cells through the downregulation of cyclin D1 protein. In addition, resveratrol dose-dependently and significantly downregulated the expression of anti-apoptotic protein includes Bcl-2, Bcl-xL and Mcl-1 and also activates cleavage caspase-9 and-3 via the downregulation of procaspase-9 and -3 in a dose-dependent manner which indicates that involvement of intrinsic mitochondria-mediated apoptotic pathway. In conclusion, resveratrol increases cellular cytotoxicity and inhibits the proliferation of B103 neuroblastoma cells by inducing mitochondria-mediated intrinsic caspase dependent pathway which suggests this natural compound could be used as therapeutic purposes for neuroblastoma malignancies.
AbstractList Resveratrol, a natural compound, has been shown to possess anti-cancer, anti-aging, anti-inflammatory, anti-microbial, and neuroprotective activities. In this study, we examined the antiproliferative and cytotoxicity properties of resveratrol in Rat B103 neuroblastoma cells; although it’s molecular mechanisms for the biological effects are not fully defined. Here, we examined the cellular cytotoxicity of resveratrol by cell viability assay, antiproliferation by BrdU assay, DNA fragmentation by DNA ladder assay, activation of caspases and Bcl-2 family proteins were detected by western blot analyses. The results of our investigation suggest that resveratrol increased cellular cytotoxicity of Rat B103 neuroblastoma cells in a dose-and time-dependent manner with IC50 of 17.86 μM at 48 h. On the other hand, incubation of neuroblastoma cells with resveratrol resulted in S-phase cell cycle arrests which dose-dependently and significantly reduced BrdU positive cells through the downregulation of cyclin D1 protein. In addition, resveratrol dose-dependently and significantly downregulated the expression of anti-apoptotic protein includes Bcl-2, Bcl-xL and Mcl-1 and also activates cleavage caspase-9 and-3 via the downregulation of procaspase-9 and -3 in a dose-dependent manner which indicates that involvement of intrinsic mitochondria-mediated apoptotic pathway. In conclusion, resveratrol increases cellular cytotoxicity and inhibits the proliferation of B103 neuroblastoma cells by inducing mitochondria-mediated intrinsic caspase dependent pathway which suggests this natural compound could be used as therapeutic purposes for neuroblastoma malignancies. KCI Citation Count: 19
Resveratrol, a natural compound, has been shown to possess anti-cancer, anti-aging, anti-inflammatory, anti-microbial, and neuroprotective activities. In this study, we examined the antiproliferative and cytotoxicity properties of resveratrol in Rat B103 neuroblastoma cells; although it's molecular mechanisms for the biological effects are not fully defined. Here, we examined the cellular cytotoxicity of resveratrol by cell viability assay, antiproliferation by BrdU assay, DNA fragmentation by DNA ladder assay, activation of caspases and Bcl-2 family proteins were detected by western blot analyses. The results of our investigation suggest that resveratrol increased cellular cytotoxicity of Rat B103 neuroblastoma cells in a dose-and time-dependent manner with IC 50 of 17.86 µM at 48 h. On the other hand, incubation of neuroblastoma cells with resveratrol resulted in S-phase cell cycle arrests which dose-dependently and significantly reduced BrdU positive cells through the downregulation of cyclin D1 protein. In addition, resveratrol dose-dependently and significantly downregulated the expression of anti-apoptotic protein includes Bcl-2, Bcl-xL and Mcl-1 and also activates cleavage caspase-9 and-3 via the downregulation of procaspase-9 and -3 in a dose-dependent manner which indicates that involvement of intrinsic mitochondria-mediated apoptotic pathway. In conclusion, resveratrol increases cellular cytotoxicity and inhibits the proliferation of B103 neuroblastoma cells by inducing mitochondria-mediated intrinsic caspase dependent pathway which suggests this natural compound could be used as therapeutic purposes for neuroblastoma malignancies.
Resveratrol, a natural compound, has been shown to possess anti-cancer, anti-aging, anti-inflammatory, anti-microbial, and neuroprotective activities. In this study, we examined the antiproliferative and cytotoxicity properties of resveratrol in Rat B103 neuroblastoma cells; although it's molecular mechanisms for the biological effects are not fully defined. Here, we examined the cellular cytotoxicity of resveratrol by cell viability assay, antiproliferation by BrdU assay, DNA fragmentation by DNA ladder assay, activation of caspases and Bcl-2 family proteins were detected by western blot analyses. The results of our investigation suggest that resveratrol increased cellular cytotoxicity of Rat B103 neuroblastoma cells in a dose-and time-dependent manner with IC(50) of 17.86 µM at 48 h. On the other hand, incubation of neuroblastoma cells with resveratrol resulted in S-phase cell cycle arrests which dose-dependently and significantly reduced BrdU positive cells through the downregulation of cyclin D1 protein. In addition, resveratrol dose-dependently and significantly downregulated the expression of anti-apoptotic protein includes Bcl-2, Bcl-xL and Mcl-1 and also activates cleavage caspase-9 and-3 via the downregulation of procaspase-9 and -3 in a dose-dependent manner which indicates that involvement of intrinsic mitochondria-mediated apoptotic pathway. In conclusion, resveratrol increases cellular cytotoxicity and inhibits the proliferation of B103 neuroblastoma cells by inducing mitochondria-mediated intrinsic caspase dependent pathway which suggests this natural compound could be used as therapeutic purposes for neuroblastoma malignancies.
Author Huh, Sung-Oh
Kim, Nam-Ho
Kim, Seung-Hyuk
Oh, Sung-Min
Rahman, Md Ataur
AuthorAffiliation Department of Pharmacology, College of Medicine, Institute of Natural Medicine, Hallym University, Chuncheon 200-702, Korea
AuthorAffiliation_xml – name: Department of Pharmacology, College of Medicine, Institute of Natural Medicine, Hallym University, Chuncheon 200-702, Korea
Author_xml – sequence: 1
  givenname: Md Ataur
  surname: Rahman
  fullname: Rahman, Md Ataur
  organization: Department of Pharmacology, College of Medicine, Institute of Natural Medicine, Hallym University, Chuncheon 200-702, Korea
– sequence: 2
  givenname: Nam-Ho
  surname: Kim
  fullname: Kim, Nam-Ho
– sequence: 3
  givenname: Seung-Hyuk
  surname: Kim
  fullname: Kim, Seung-Hyuk
– sequence: 4
  givenname: Sung-Min
  surname: Oh
  fullname: Oh, Sung-Min
– sequence: 5
  givenname: Sung-Oh
  surname: Huh
  fullname: Huh, Sung-Oh
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23118555$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001711965$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNpVkc1O3DAUhS1EVaaUF-gCeckmqX_ixN4gjRAtSEiVKrq2HP-AOxk7ss2IeXschiK6uov7nWP5fl_AcYjBAvANo7bDov---TvPLUGYtLhvWUsJPgIrggRtKCfDMVhhQvqmY5icgLOc_YgQZ4hxJD6DE0Ix5oyxFdivQ_FzipN3NqnidxaqYKDel1jis9fQOmd1yTA6mGzeLVCloQ9w60vUjzGY5FWztcarYg1Uc5xLzD4vSIXhiBGFwT6lOE4ql7hVUNtpyl_BJ6embM_e5in48-P6_uqmufv18_ZqfdfojrLScKLQSGyPCCIYDY4NZDDYcaW7gXbWiVGNveGCCW0c7bBVFgtjDB0EZ1QZegouDr0hObnRXkblX-dDlJsk17_vbyWtxxlERS8P6Pw01g9pG0pSk5yT36q0fw3-vwn-sdbsJO14vXRfC8ihQKeYc7LuPYuRXLTJRZtctEncSyartho6__jqe-SfJPoCO12aKQ
CitedBy_id crossref_primary_10_1016_j_jnutbio_2021_108768
crossref_primary_10_5897_AJB2018_16604
crossref_primary_10_1016_j_ejmech_2019_111738
crossref_primary_10_1155_2020_7534693
crossref_primary_10_1002_biof_1221
crossref_primary_10_3390_biom13030563
crossref_primary_10_1007_s00044_014_1283_7
crossref_primary_10_1021_acs_jafc_6b04549
crossref_primary_10_1515_revneuro_2020_0021
crossref_primary_10_17221_401_2015_CJFS
crossref_primary_10_1016_j_taap_2021_115510
crossref_primary_10_1016_j_imu_2022_101046
crossref_primary_10_1016_j_bcp_2023_115550
crossref_primary_10_1038_emm_2015_116
crossref_primary_10_1371_journal_pone_0064535
crossref_primary_10_1016_S1875_5364_13_60001_1
crossref_primary_10_3897_pharmacia_71_e122169
crossref_primary_10_1016_j_ijbiomac_2023_127162
crossref_primary_10_1016_j_bbagen_2016_01_017
crossref_primary_10_1002_jbt_22925
crossref_primary_10_3389_fcell_2020_00283
crossref_primary_10_3390_biomedicines8110517
crossref_primary_10_1111_jfbc_13008
crossref_primary_10_1016_j_fct_2014_03_017
crossref_primary_10_1080_07391102_2021_1877822
crossref_primary_10_4196_kjpp_2016_20_4_325
crossref_primary_10_1042_BSR20200257
crossref_primary_10_3390_biom10111469
crossref_primary_10_3390_app14114534
crossref_primary_10_3389_fphar_2021_639628
crossref_primary_10_3390_biomedicines9010005
crossref_primary_10_1016_j_taap_2019_03_008
crossref_primary_10_1016_j_bbagen_2016_10_025
crossref_primary_10_1016_j_jep_2020_113435
crossref_primary_10_18632_oncotarget_17879
crossref_primary_10_3390_ijms20040925
crossref_primary_10_3390_antiox10010023
Cites_doi 10.1126/science.275.5297.218
10.1007/s11095-008-9723-z
10.2174/157488908783421492
10.1093/carcin/21.3.525
10.1038/sj.onc.1207558
10.1007/s12094-007-0091-7
10.1016/S0009-9120(96)00155-5
10.1200/JCO.1999.17.9.2941
10.1016/S0140-6736(07)60983-0
10.1016/S0140-6736(77)92818-5
10.1093/jn/130.2.467S
10.1006/excr.2000.4839
10.1182/blood.V54.1.186.186
10.1172/JCI26252
10.1016/j.cellsig.2003.08.007
10.1182/blood.V88.6.1936.bloodjournal8861936
10.1002/mnfr.200800148
10.2174/156720209787466019
10.1006/bbrc.1998.9916
10.1074/jbc.274.29.20049
10.1002/ijc.11720
10.1158/1078-0432.CCR-07-1750
10.1182/blood.V92.3.996
10.1016/j.molonc.2008.07.002
10.1016/j.bcp.2008.08.002
10.1126/science.278.5340.1073
10.1016/S1383-5742(99)00057-5
ContentType Journal Article
Copyright Copyright © 2012 The Korean Physiological Society and The Korean Society of Pharmacology 2012
Copyright_xml – notice: Copyright © 2012 The Korean Physiological Society and The Korean Society of Pharmacology 2012
DBID NPM
AAYXX
CITATION
5PM
ACYCR
DOI 10.4196/kjpp.2012.16.5.321
DatabaseName PubMed
CrossRef
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle PubMed
CrossRef
DatabaseTitleList

PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 2093-3827
EndPage 326
ExternalDocumentID oai_kci_go_kr_ARTI_300879
10_4196_kjpp_2012_16_5_321
23118555
Genre Journal Article
GroupedDBID 53G
NPM
---
.UV
5-W
5GY
8JR
8XY
9ZL
AAYXX
ABDBF
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
E3Z
EBD
EF.
ESX
F5P
GX1
HYE
KVFHK
MK0
OK1
P2P
P5Y
P6G
RPM
TR2
TUS
5PM
ABPTK
ACYCR
ID FETCH-LOGICAL-c435t-82a0b2e60202107f5727d1f8ac4734ef9bab6d8959cdf341eae19ddd379853ad3
IEDL.DBID RPM
ISSN 1226-4512
IngestDate Tue Nov 21 21:37:18 EST 2023
Tue Apr 09 21:35:58 EDT 2024
Fri Aug 23 03:07:15 EDT 2024
Wed Jun 21 01:53:20 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Neuroblastoma
Cyclin D1
Resveratrol
Apoptosis
Bcl-2 family
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c435t-82a0b2e60202107f5727d1f8ac4734ef9bab6d8959cdf341eae19ddd379853ad3
Notes G704-000764.2012.16.5.005
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484516/
PMID 23118555
PageCount 6
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_300879
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3484516
crossref_primary_10_4196_kjpp_2012_16_5_321
pubmed_primary_23118555
PublicationCentury 2000
PublicationDate 2012-10-01
PublicationDateYYYYMMDD 2012-10-01
PublicationDate_xml – month: 10
  year: 2012
  text: 2012-10-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle The Korean journal of physiology & pharmacology
PublicationTitleAlternate Korean J Physiol Pharmacol
PublicationYear 2012
Publisher The Korean Physiological Society and The Korean Society of Pharmacology
대한약리학회
Publisher_xml – name: The Korean Physiological Society and The Korean Society of Pharmacology
– name: 대한약리학회
References 9127691 - Clin Biochem. 1997 Mar;30(2):91-113
18761329 - Biochem Pharmacol. 2008 Dec 1;76(11):1554-62
9920811 - Biochem Biophys Res Commun. 1999 Jan 27;254(3):739-43
15077156 - Oncogene. 2004 Apr 12;23(16):2950-66
8840993 - Cancer Res. 1996 Oct 15;56(20):4743-8
10721931 - J Nutr. 2000 Feb;130(2S Suppl):467S-471S
1991500 - Exp Hematol. 1991 Feb;19(2):95-100
16200200 - J Clin Invest. 2005 Oct;115(10):2665-72
19072742 - Mol Nutr Food Res. 2009 Jan;53(1):115-28
18791811 - Pharm Res. 2009 Jan;26(1):211-7
15517885 - Anticancer Res. 2004 Sep-Oct;24(5A):2783-840
14750165 - Int J Cancer. 2004 Mar 20;109(2):167-73
14636884 - Cell Signal. 2004 Feb;16(2):139-44
17586306 - Lancet. 2007 Jun 23;369(9579):2106-20
19355928 - Curr Neurovasc Res. 2009 Feb;6(1):70-81
18221243 - Recent Pat CNS Drug Discov. 2008 Jan;3(1):61-9
18347188 - Clin Cancer Res. 2008 Mar 15;14(6):1849-58
9353183 - Science. 1997 Nov 7;278(5340):1073-7
19383347 - Mol Oncol. 2008 Oct;2(3):261-71
9680369 - Blood. 1998 Aug 1;92(3):996-1002
10561374 - J Clin Oncol. 1999 Sep;17(9):2941-53
10688873 - Carcinogenesis. 2000 Mar;21(3):525-30
10518003 - Mutat Res. 1999 Jul 16;428(1-2):305-27
67373 - Lancet. 1977 Apr 16;1(8016):862-3
8822910 - Blood. 1996 Sep 15;88(6):1936-43
10739651 - Exp Cell Res. 2000 Apr 10;256(1):50-7
17720650 - Clin Transl Oncol. 2007 Aug;9(8):478-83
10400609 - J Biol Chem. 1999 Jul 16;274(29):20049-52
8985016 - Science. 1997 Jan 10;275(5297):218-20
312670 - Blood. 1979 Jul;54(1):186-95
Roy (10.4196/kjpp.2012.16.5.321_ref11) 2009; 26
Thorburn (10.4196/kjpp.2012.16.5.321_ref18) 2004; 16
Minden (10.4196/kjpp.2012.16.5.321_ref28) 1979; 54
Pallàs (10.4196/kjpp.2012.16.5.321_ref7) 2008; 3
Maris (10.4196/kjpp.2012.16.5.321_ref2) 2007; 369
Pozo-Guisado (10.4196/kjpp.2012.16.5.321_ref9) 2004; 109
Soleas (10.4196/kjpp.2012.16.5.321_ref17) 1997; 30
Castel (10.4196/kjpp.2012.16.5.321_ref3) 2007; 9
Kelloff (10.4196/kjpp.2012.16.5.321_ref14) 2000; 130
Buick (10.4196/kjpp.2012.16.5.321_ref27) 1977; 1
Lavrik (10.4196/kjpp.2012.16.5.321_ref21) 2005; 115
Clément (10.4196/kjpp.2012.16.5.321_ref16) 1998; 92
Reed (10.4196/kjpp.2012.16.5.321_ref25) 1999; 17
Roccaro (10.4196/kjpp.2012.16.5.321_ref5) 2008; 14
Debatin (10.4196/kjpp.2012.16.5.321_ref19) 2004; 23
Antonsson (10.4196/kjpp.2012.16.5.321_ref24) 2000; 256
Pallàs (10.4196/kjpp.2012.16.5.321_ref6) 2009; 6
Sporn (10.4196/kjpp.2012.16.5.321_ref15) 2000; 21
Jang (10.4196/kjpp.2012.16.5.321_ref8) 1997; 275
Aggarwal (10.4196/kjpp.2012.16.5.321_ref12) 2004; 24
Ibrado (10.4196/kjpp.2012.16.5.321_ref30) 1996; 56
Shakibaei (10.4196/kjpp.2012.16.5.321_ref4) 2009; 53
Surh (10.4196/kjpp.2012.16.5.321_ref22) 1999; 428
Komina (10.4196/kjpp.2012.16.5.321_ref10) 2008; 76
Bénard (10.4196/kjpp.2012.16.5.321_ref1) 2008; 2
Wolf (10.4196/kjpp.2012.16.5.321_ref20) 1999; 274
Carbó (10.4196/kjpp.2012.16.5.321_ref23) 1999; 254
Datta (10.4196/kjpp.2012.16.5.321_ref29) 1996; 88
Bertoncello (10.4196/kjpp.2012.16.5.321_ref26) 1991; 19
Hong (10.4196/kjpp.2012.16.5.321_ref13) 1997; 278
References_xml – volume: 275
  start-page: 218
  year: 1997
  ident: 10.4196/kjpp.2012.16.5.321_ref8
  publication-title: Science
  doi: 10.1126/science.275.5297.218
  contributor:
    fullname: Jang
– volume: 26
  start-page: 211
  year: 2009
  ident: 10.4196/kjpp.2012.16.5.321_ref11
  publication-title: Pharm Res
  doi: 10.1007/s11095-008-9723-z
  contributor:
    fullname: Roy
– volume: 3
  start-page: 61
  year: 2008
  ident: 10.4196/kjpp.2012.16.5.321_ref7
  publication-title: Recent Pat CNS Drug Discov
  doi: 10.2174/157488908783421492
  contributor:
    fullname: Pallàs
– volume: 21
  start-page: 525
  year: 2000
  ident: 10.4196/kjpp.2012.16.5.321_ref15
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/21.3.525
  contributor:
    fullname: Sporn
– volume: 56
  start-page: 4743
  year: 1996
  ident: 10.4196/kjpp.2012.16.5.321_ref30
  publication-title: Cancer Res
  contributor:
    fullname: Ibrado
– volume: 23
  start-page: 2950
  year: 2004
  ident: 10.4196/kjpp.2012.16.5.321_ref19
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1207558
  contributor:
    fullname: Debatin
– volume: 9
  start-page: 478
  year: 2007
  ident: 10.4196/kjpp.2012.16.5.321_ref3
  publication-title: Clin Transl Oncol
  doi: 10.1007/s12094-007-0091-7
  contributor:
    fullname: Castel
– volume: 30
  start-page: 91
  year: 1997
  ident: 10.4196/kjpp.2012.16.5.321_ref17
  publication-title: Clin Biochem
  doi: 10.1016/S0009-9120(96)00155-5
  contributor:
    fullname: Soleas
– volume: 17
  start-page: 2941
  year: 1999
  ident: 10.4196/kjpp.2012.16.5.321_ref25
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1999.17.9.2941
  contributor:
    fullname: Reed
– volume: 369
  start-page: 2106
  year: 2007
  ident: 10.4196/kjpp.2012.16.5.321_ref2
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)60983-0
  contributor:
    fullname: Maris
– volume: 19
  start-page: 95
  year: 1991
  ident: 10.4196/kjpp.2012.16.5.321_ref26
  publication-title: Exp Hematol
  contributor:
    fullname: Bertoncello
– volume: 1
  start-page: 862
  year: 1977
  ident: 10.4196/kjpp.2012.16.5.321_ref27
  publication-title: Lancet
  doi: 10.1016/S0140-6736(77)92818-5
  contributor:
    fullname: Buick
– volume: 130
  start-page: 467S
  issue: 2S Suppl
  year: 2000
  ident: 10.4196/kjpp.2012.16.5.321_ref14
  publication-title: J Nutr
  doi: 10.1093/jn/130.2.467S
  contributor:
    fullname: Kelloff
– volume: 256
  start-page: 50
  year: 2000
  ident: 10.4196/kjpp.2012.16.5.321_ref24
  publication-title: Exp Cell Res
  doi: 10.1006/excr.2000.4839
  contributor:
    fullname: Antonsson
– volume: 54
  start-page: 186
  year: 1979
  ident: 10.4196/kjpp.2012.16.5.321_ref28
  publication-title: Blood
  doi: 10.1182/blood.V54.1.186.186
  contributor:
    fullname: Minden
– volume: 115
  start-page: 2665
  year: 2005
  ident: 10.4196/kjpp.2012.16.5.321_ref21
  publication-title: J Clin Invest
  doi: 10.1172/JCI26252
  contributor:
    fullname: Lavrik
– volume: 16
  start-page: 139
  year: 2004
  ident: 10.4196/kjpp.2012.16.5.321_ref18
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2003.08.007
  contributor:
    fullname: Thorburn
– volume: 88
  start-page: 1936
  year: 1996
  ident: 10.4196/kjpp.2012.16.5.321_ref29
  publication-title: Blood
  doi: 10.1182/blood.V88.6.1936.bloodjournal8861936
  contributor:
    fullname: Datta
– volume: 53
  start-page: 115
  year: 2009
  ident: 10.4196/kjpp.2012.16.5.321_ref4
  publication-title: Mol Nutr Food Res
  doi: 10.1002/mnfr.200800148
  contributor:
    fullname: Shakibaei
– volume: 6
  start-page: 70
  year: 2009
  ident: 10.4196/kjpp.2012.16.5.321_ref6
  publication-title: Curr Neurovasc Res
  doi: 10.2174/156720209787466019
  contributor:
    fullname: Pallàs
– volume: 254
  start-page: 739
  year: 1999
  ident: 10.4196/kjpp.2012.16.5.321_ref23
  publication-title: Biochem Biophys Res Commun
  doi: 10.1006/bbrc.1998.9916
  contributor:
    fullname: Carbó
– volume: 274
  start-page: 20049
  year: 1999
  ident: 10.4196/kjpp.2012.16.5.321_ref20
  publication-title: J Biol Chem
  doi: 10.1074/jbc.274.29.20049
  contributor:
    fullname: Wolf
– volume: 109
  start-page: 167
  year: 2004
  ident: 10.4196/kjpp.2012.16.5.321_ref9
  publication-title: Int J Cancer
  doi: 10.1002/ijc.11720
  contributor:
    fullname: Pozo-Guisado
– volume: 14
  start-page: 1849
  year: 2008
  ident: 10.4196/kjpp.2012.16.5.321_ref5
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-1750
  contributor:
    fullname: Roccaro
– volume: 92
  start-page: 996
  year: 1998
  ident: 10.4196/kjpp.2012.16.5.321_ref16
  publication-title: Blood
  doi: 10.1182/blood.V92.3.996
  contributor:
    fullname: Clément
– volume: 2
  start-page: 261
  year: 2008
  ident: 10.4196/kjpp.2012.16.5.321_ref1
  publication-title: Mol Oncol
  doi: 10.1016/j.molonc.2008.07.002
  contributor:
    fullname: Bénard
– volume: 76
  start-page: 1554
  year: 2008
  ident: 10.4196/kjpp.2012.16.5.321_ref10
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2008.08.002
  contributor:
    fullname: Komina
– volume: 24
  start-page: 2783
  year: 2004
  ident: 10.4196/kjpp.2012.16.5.321_ref12
  publication-title: Anticancer Res
  contributor:
    fullname: Aggarwal
– volume: 278
  start-page: 1073
  year: 1997
  ident: 10.4196/kjpp.2012.16.5.321_ref13
  publication-title: Science
  doi: 10.1126/science.278.5340.1073
  contributor:
    fullname: Hong
– volume: 428
  start-page: 305
  year: 1999
  ident: 10.4196/kjpp.2012.16.5.321_ref22
  publication-title: Mutat Res
  doi: 10.1016/S1383-5742(99)00057-5
  contributor:
    fullname: Surh
SSID ssib008505809
ssj0064464
Score 2.1373606
Snippet Resveratrol, a natural compound, has been shown to possess anti-cancer, anti-aging, anti-inflammatory, anti-microbial, and neuroprotective activities. In this...
SourceID nrf
pubmedcentral
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 321
SubjectTerms Original
약리학
Title Antiproliferative and cytotoxic effects of resveratrol in mitochondria-mediated apoptosis in rat b103 neuroblastoma cells
URI https://www.ncbi.nlm.nih.gov/pubmed/23118555
https://pubmed.ncbi.nlm.nih.gov/PMC3484516
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001711965
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX The Korean Journal of Physiology & Pharmacology, 2012, 16(5), , pp.321-326
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nj9MwELW2e-KCgOWjsKyMhLigpHGcz2OpWBakrlYrVurNsmMbQlsnarKI_ntmnHbVcuTiHDK2nMzE7zkavyHkfWQzgB1lAwCPKEhsnAeSZUXAM2Y5VxlWZMRsi-vs6i75tkgXJyTdn4XxSfuVqkO3Woeu_ulzK9t1NdnniU1u5jOeFFhfdjIio5zzf7boBWC616QalmPAe68hxYBnBNArHk7OJBB5k-WvFiUrWRyyLExDHmPdGCA8gGF49O8AqEZuYw8w6jh_8gCQLp-QxzsmSafDjJ-SE-OekbOpg130eks_UJ_b6X-an5Ht1PV1iwV6rBmkvql0ms62fdM3f-qKDiLGHW0svTXdbzQCa1o7OodPHpZIpyFSg7kv7GE0nbZN2zdd3aHJrezpJxZx6pU-FPBxmIKkM7Nadc_J3eXn77OrYFd0IaiAOfVBEctIxSYDGgm7wdymQHA0s4WskpwnxpZKqkwXZVpW2gIEGmlYqbXmeQnILzV_QU5d48wrQksUPoxkVam0BMNYJdJCg6J_QGoYG5OP-zcs2kFbQ8CeBF0j0DUCXSNYJlIBrhmTd-AEsaxqgZLYeP3RiOVGAPH_Kjhq65Vj8nLwzMN4e2-OSX7kswcDHOv4DkSdl9neRdnr_-75hjzCJxhS_87Jab-5N2-BwvTqgoy-LBi01zfzCx--fwG-RPBa
link.rule.ids 230,315,733,786,790,891,27955,27956,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa28QAv3AajXI2EeEFJ4zjXx1IxdbBOaNrQ3ixfIbR1ojZDlF_PsdNM7d7gJX3ISRTrs_19pzr-DkLvIpMB7QgTAHlEQWLiPOAkKwKaEUOpyFxHRldtcZZNLpPPV-nVHkr7szC-aF-KKrTzRWirH762slnIYV8nNvw6HdOkcP1lh_voDqzXOL2VpBfA6t6VqtuQgfG9ixQBpRHAc3F3diaBuTec_WycaSWJQ5KFaUhj1zkGJA-wmDv8t0VV-3Zptlhqt4Jyi5KOH6Bv_WC6SpRZeN2KUP655fP4z6N9iO5vRCoedbcfoT1tH6PDkYUEfbHG77EvG_X_xx-i9ci2VeN6_xjduYhjbhUer9u6rX9XEnf-yCtcG3yuV79cEETjyuIp7Caw-1oFiyCY-p4hWuFRUzdtvapWLuSct_gjiSj2JiICpD58AsdjPZ-vnqDL408X40mw6ecQSBBlbVDEPBKxzkChQqKZmxS0kyKm4DLJaaJNKbjIVFGmpVQG2FVzTUqlFM1LEBVc0afowNZWP0O4dJ6KEZdSpCUExiLhBi7OTxD0EiED9KGHjjWdbQeDdMdhzhzmzGHOSMZSBpgP0FtAl81kxZzbtvv9XrPZkkFOccKos-0rB-iog_zmff00GaB8ZzLcBLh37d4BiL2D9wbS5__95Bt0d3IxPWWnJ2dfXqB7bjRdheFLdNAur_UrUEqteO3XxV8M6hBh
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9NAFB7RIiEuZSlLWAcJcUFexuP1GAJRC6SqKipVXEazgptkbCUuIvx63oyTKumxF_vgZ8ujb2a-71nP30PofWxyoB1hAiCPOEhNUgSc5GVAc2IoFbnryOiqLU7yo_P060V2sdXqyxftS1GHdjYPbf3b11a2cxlt6sSi08mIpqXrLxu1ykR76C6s2aS4kaiXwOzemarflIH1vZMUAbURwL1J__9MCvMvml62zriSJCHJwyykieseA7IHmMz9ALhFV3t2YbaYareKcouWxg_Qz82A-mqUaXjViVD-u-H1eKsRP0QHa7GKh33II3RH28focGghUZ-v8Afsy0f9d_lDtBrarm5dDyCjezdxzK3Co1XXdM3fWuLeJ3mJG4PP9PKPC4JoXFs8gV0FdmGrYDEEE987RCs8bJu2a5b10oWc8Q5_IjHF3kxEgOSHV-B4pGez5RN0Pv7yY3QUrPs6BBLEWReUCY9FonNQqpBwFiYDDaWIKblMC5pqUwkuclVWWSWVAZbVXJNKKUWLCsQFV_Qp2reN1c8Rrpy3YsylFFkFgYlIuYGD8xUE3UTIAH3cwMfa3r6DQdrjcGcOd-ZwZyRnGQPcB-gdIMymsmbOddudfzVsumCQWxwz6uz7qgF61sN-_bzNVBmgYmdCXAe4Z-1eAZi9k_ca1he3vvMtunf6ecy-H598e4nuu8H0hYav0H63uNKvQTB14o1fGv8BmJES4Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antiproliferative+and+Cytotoxic+Effects+of+Resveratrol+in+Mitochondria-Mediated+Apoptosis+in+Rat+B103+Neuroblastoma+Cells&rft.jtitle=The+Korean+journal+of+physiology+%26+pharmacology&rft.au=Rahman%2C+Md.+Ataur&rft.au=Kim%2C+Nam-Ho&rft.au=Kim%2C+Seung-Hyuk&rft.au=Oh%2C+Sung-Min&rft.date=2012-10-01&rft.issn=1226-4512&rft.eissn=2093-3827&rft.volume=16&rft.issue=5&rft.spage=321&rft_id=info:doi/10.4196%2Fkjpp.2012.16.5.321&rft.externalDBID=n%2Fa&rft.externalDocID=10_4196_kjpp_2012_16_5_321
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1226-4512&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1226-4512&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1226-4512&client=summon